Authorized Generics, Competition, and Consumer Prices
In strategy and antitrust assignments, Analysis Group has developed significant expertise assessing the competitive impact of generic pharmaceuticals. Academic affiliate Professor Ernst R. Berndt, Managing Principal Edward Tuttle, Vice President Richard Mortimer, and a client co-authored "Authorized Generic Drugs, Price Competition and Consumers' Welfare" (Health Affairs, 26, no 3, 2007). In the study, the authors conclude that authorized generics tend to enhance competition and work to the benefit of patients. When drug patents expire, generic equivalents usually enter the market, drastically reducing prices.
Associated Experts & Staff